Direct-to-consumer buyers are more clinically informed than ever. They are increasingly looking beyond marketing claims, reading PubMed abstracts and scrutinising the evidence behind the ingredients they buy. They understand the distinction between "clinically studied ingredient" and "clinically studied dose,” and are unwilling to accept claims that blur the two.
Proprietary blends that obscure individual quantities, “research-backed” claims based primarily on animal or in vitro studies and ingredient lists that rely on traditional-use evidence rather than human clinical trials can all undermine consumer trust.
Three recent ingredient examples are instructive here: not because the ingredients themselves are unusual but because they demonstrate what “the evidence isn’t there yet” can mean in practice.
NMN
Nicotinamide mononucleotide (NMN) has been one of the most heavily marketed longevity ingredients in recent years. A 2024 systematic review and meta-analysis of randomised controlled trials (RCTs), published in Critical Reviews in Food Science and Nutrition, collected the available human data on NMN and glucose and lipid metabolism. It found no significant effect on fasting glucose, HbA1c or any measured lipid marker.1
A separate multicentre, dose-dependent RCT in healthy middle-aged adults reported other positive signals — mainly around NAD+ levels — during short study periods.2 But a pooled result of "no significant effect" on the metabolic outcomes that people actually buy the ingredient for is not the same as a body of evidence that supports a metabolic-health claim.
According to Johnny, that distinction — an interesting mechanism versus a replicated/consistent clinical effect — is exactly the one brands need to start being explicit about.